Table 3.
Multivariate analysis of factors predicting recurrence-free survival
| Variable | Recurrence-free survival | ||
|---|---|---|---|
| HR | 95% CI | p | |
| Model A | |||
| Primary tumor (T) (III/IV vs I/II) | 2.404 | 1.537–3.759 | < 0.001 |
| Lymph nodes metastasis (N) (Yes vs No) | 1.451 | 0.944–2.229 | 0.090 |
| TNM Stage (III/IV vs I/II) | 1.025 | 0.589–1.783 | 0.931 |
| CD44 (High vs Low) | 1.476 | 1.062–2.051 | 0.020 |
| Model B | |||
| Primary tumor (T) (III/IV vs I/II) | 2.341 | 1.482–3.697 | < 0.001 |
| Lymph nodes metastasis (N) (Yes vs No) | 1.368 | 0.880–2.126 | 0.164 |
| TNM Stage (III/IV vs I/II) | 1.024 | 0.579–1.871 | 0.934 |
| CD44v6 (Pos. vs Neg.) | 1.350 | 0.975–1.871 | 0.071 |
| Model C | |||
| Primary tumor (T) (III/IV vs I/II) | 2.665 | 1.686–4.212 | < 0.001 |
| Lymph nodes metastasis (N) (Yes vs No) | 1.441 | 0.934–2.223 | 0.098 |
| TNM Stage (III/IV vs I/II) | 0.933 | 0.528–1.649 | 0.810 |
| CD44v8-10 (Pos. vs Neg.) | 1.491 | 1.092–2.036 | 0.012 |
TNM size of primary tumor-node metastasis-distant metastasis, CD44 cluster of differentiation 44, CD44v CD44 variant, Neg negative expression, Pos positive expression